Seer, Inc. Class A (SEER)

In the past six months, Seer, Inc.'s stock has experienced several notable events. The company announced its fourth quarter and full-year 2025 financial results on February 26, 2026, which led to a pre-market increase of approximately 4% in its shares. Previously, in November 2025, Seer reported its Q3 2025 earnings, with revenue of $4.1 million, an improved gross margin of 51%, and a reduced net loss of $18.2 million. The company maintained a strong cash position of $251 million and had repurchased approximately $22 million in shares. Other significant events include external validation of Seer's Proteograph platform through a Nature Genetics study published in December 2025, and presentations at HUPO 2025 in November 2025. A partnership announcement with RetinalGenix Technologies to explore early detection of neurodegenerative and systemic diseases may also be contributing to optimism around Seer's commercial traction. Despite these positive developments, the stock has historically shown negative price reactions following positive news, and it remains under pressure year-to-date as investors await clearer signs of revenue growth and a path to profitability. The stock has traded within a 52-week range of $1.62 to $2.41.

Information regarding specific demand seasonality for Seer, Inc.'s products and services is not explicitly available. The company has noted that the level of demand for its products, particularly the Proteograph Product Suite, may vary significantly from period to period. This variability is influenced by factors such as the company's ability to drive adoption in its target markets and expand into new ones, as well as its relationships with third-party distributorships and their effectiveness in promoting and selling products. General economic conditions and financial markets could also adversely affect demand.

Seer, Inc. is a biotechnology and life sciences company focused on decoding the proteome to enhance the understanding of biology and disease and enable novel insights. The company operates within the biotechnology and life sciences sectors, with its primary industry noted as decision/risk analysis and biotechnology. Seer's main product is the Proteograph™ Product Suite, an integrated solution that utilizes proprietary engineered nanoparticle (NP) technology, consumables, automation instrumentation, and software to conduct deep, unbiased proteomic analysis at scale. This suite is designed to provide researchers with comprehensive access to the proteome, facilitating the discovery of new biomarkers and the investigation of complex biological processes. The Proteograph Product Suite is intended for research use only and not for diagnostic procedures. The company also offers the Proteograph Analysis Suite, which aims to simplify proteomics analysis and data interpretation.

Seer, Inc. is headquartered in Redwood City, California, and was incorporated in Delaware in March 2017. In December 2020, the company established a wholly-owned subsidiary, Seer Securities Corporation, in Massachusetts. The company's operations and market presence appear to be primarily within the United States.

In the past year, Seer's brand reputation has been positively influenced by external validation of its Proteograph platform. A genome-wide association study utilizing the company's platform was published in Nature Genetics in December 2025, highlighting its importance for identifying drug targets and biomarkers. Additionally, Seer and its collaborators unveiled new data demonstrating the translational power of deep proteomics at HUPO 2025 in November 2025. The company also presented at the CG MedTech, Diagnostics and Digital Health & Services Forum and the Morgan Stanley 23rd Annual Global Healthcare Conference in late 2025, showcasing its proteomics innovations and path forward. A partnership announcement with RetinalGenix Technologies to explore early detection of neurodegenerative and systemic diseases further contributes to a positive perception of the company's scientific and commercial progress. While there isn't explicit information about negative events directly impacting brand reputation, the general investor caution surrounding small-cap biotech companies with limited revenue and ongoing cash burn could indirectly affect overall perception.

Seer, Inc. has 95 institutional owners and shareholders. Major institutional owners include Softbank Group Corp, Siren, L.L.C., Vanguard Group Inc, Acadian Asset Management Llc, BlackRock, Inc., VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, Tang Capital Management Llc, Renaissance Technologies Llc, AJU IB Investment Co., Ltd., and Bridgeway Capital Management Inc. Individual major owners include Omid Farokhzad, who holds 9.261% of equities, and Bradley Radoff, with 2.704%.